Drug Profile
Research programme: siRNA therapeutics - Sirnaomics
Alternative Names: Acurita; STP523; STP601; STP801; STP805; STP900; STP911; STP916Latest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator Sirnaomics
- Developer Guangdong Zhongsheng Pharmaceutical; Sirnaomics
- Class Antineoplastics; Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; COVID 2019 infections; Eye disorders; Glioblastoma; Human papillomavirus infections; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Respiratory syncytial virus infections; Spinal cord injuries; Transplant rejection
Most Recent Events
- 31 Mar 2023 Discontinued - Preclinical for Age-related macular degeneration in Asia (Parenteral) (Sirnaomics Pipeline, March 2023)
- 31 Mar 2023 Discontinued - Preclinical for Age-related macular degeneration in China (Parenteral) (Sirnaomics Pipeline, March 2023)
- 31 Mar 2023 Discontinued - Preclinical for Eye disorders in USA (Parenteral) (Sirnaomics Pipeline, March 2023)